BAUDAX BIO INC (BXRX) Stock Price, Forecast & Analysis
USA - NASDAQ:BXRX - US07160F4046 - Common Stock
BXRX Key Statistics, Chart & Performance
The current stock price of BXRX is 0.1864 USD. In the past month the price decreased by -17.59%. In the past year, price decreased by -96.56%.
BXRX Latest News, Press Relases and Analysis
BXRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.63 | 887.25B | ||
| JNJ | JOHNSON & JOHNSON | 18.01 | 450.29B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.87 | 259.73B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.14 | 245.02B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 11.86 | 206.66B | ||
| MRK | MERCK & CO. INC. | 9.74 | 214.26B | ||
| PFE | PFIZER INC | 7.77 | 141.29B | ||
| SNY | SANOFI-ADR | 11.32 | 120.61B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.91B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 94.73B | ||
| ZTS | ZOETIS INC | 18.86 | 52.99B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 194.86 | 43.08B |
Related stock screener links
About BXRX
Company Profile
Baudax Bio, Inc. operates as a pharmaceutical company. The company is headquartered in Malvern, Pennsylvania and currently employs 9 full-time employees. The company went IPO on 2019-11-14. The firm is focused on developing and commercializing products for hospital and related acute care settings. The firm's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. The company is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. The company is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.
Company Info
BAUDAX BIO INC
490 Lapp Rd
Malvern PENNSYLVANIA 19355 US
CEO: Gerri A. Henwood
Employees: 9
Phone: 14843952440.0
BAUDAX BIO INC / BXRX FAQ
What does BAUDAX BIO INC do?
Baudax Bio, Inc. operates as a pharmaceutical company. The company is headquartered in Malvern, Pennsylvania and currently employs 9 full-time employees. The company went IPO on 2019-11-14. The firm is focused on developing and commercializing products for hospital and related acute care settings. The firm's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. The company is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. The company is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.
What is the stock price of BAUDAX BIO INC today?
The current stock price of BXRX is 0.1864 USD. The price increased by 0.59% in the last trading session.
What is the dividend status of BAUDAX BIO INC?
BXRX does not pay a dividend.
How is the ChartMill rating for BAUDAX BIO INC?
BXRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting BXRX stock to perform?
6 analysts have analysed BXRX and the average price target is 24.48 USD. This implies a price increase of 13033.05% is expected in the next year compared to the current price of 0.1864.
Should I buy BXRX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BXRX.
BXRX Technical Analysis
BXRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BXRX. BXRX may be in some trouble as it scores bad on both profitability and health.
BXRX Financial Highlights
Over the last trailing twelve months BXRX reported a non-GAAP Earnings per Share(EPS) of -44.16. The EPS increased by 7.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -161.54% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BXRX Forecast & Estimates
6 analysts have analysed BXRX and the average price target is 24.48 USD. This implies a price increase of 13033.05% is expected in the next year compared to the current price of 0.1864.
For the next year, analysts expect an EPS growth of 99.19% and a revenue growth -100% for BXRX